Enhancing metabolic monitoring for children and adolescents using second‐generation antipsychotics

The prevalence of children and adolescents using second‐generation antipsychotics ( SGA s) has increased significantly in recent years. In this population, SGA s are used to treat mood and behavioural disorders although considered ‘off‐label’ or not approved for these indications. Metabolic monitoring is the systematic physical health assessment of antipsychotic users utilized to detect cardiovascular and endocrine side effects and prevent adverse events such as weight gain, hyperglycaemia, hyperlipidemia, and arrhythmias. This practice ensures safe and efficacious SGA use among children and adolescents. Despite widely available, evidence‐based metabolic monitoring guidelines, rates of monitoring continue to be suboptimal; this exposes children to the unnecessary risk of developing poor cardiovascular health and long‐term disease. In this discursive paper, existing approaches to metabolic monitoring as well as challenges to implementing monitoring guidelines in practice are explored. The strengths and weaknesses of providing metabolic monitoring across outpatient psychiatry, primary care, and collaborative community settings are discussed. We suggest that there is no one‐size‐fits‐all solution to improving metabolic monitoring care for children and adolescents using SGA in all settings. However, we advocate for a pragmatic global approach to enhance safety of children and adolescents taking SGA s through collaboration among healthcare disciplines with a focus on integrating nurses as champions of metabolic monitoring.